According to the news on the Zhitong Finance APP, Alumis (ALMS.US), a clinical-stage biopharmaceutical company developing oral therapy, will issue 13.125 million shares of stock at an initial price of $16.00 per share and will be traded on NASDAQ on June 28th. The stock code is "ALMS".
Alumis also announced today that the company has agreed to privately sell 2.5 million shares to one of its existing investors, AyurMaya Capital Management Fund, LP, at a price of $16.00 per share. The total amount raised in the initial public offering and the concurrent private placement is expected to be $250 million.
It is reported that underwriters have a 30-day over-allotment option to purchase up to an additional 1,968,750 shares. The offering is expected to close on July 1, 2024. Morgan Stanley, Leerink Partners, Cantor Fitzgerald, and Guggenheim Securities are the joint book-running managers of the transaction.